AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline UpdatesGlobeNewsWire • 11/04/21
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with SagardGlobeNewsWire • 10/25/21
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular PsoriasisGlobeNewsWire • 10/02/21
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/09/21
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor IndicationBenzinga • 08/18/21
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid TumorsGlobeNewsWire • 08/17/21
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline UpdatesGlobeNewsWire • 08/09/21
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline UpdatesGlobeNewsWire • 05/04/21
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/21
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in EuropeGlobeNewsWire • 04/23/21
AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder StudyBenzinga • 03/08/21
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 02/22/21